Sanofi’s Euroapi Launches as Stand-alone $1-Bn CDMO
By

Euroapi, a CDMO of small-molecule APIs spun off from Sanofi, has launched as a stand-alone publicly traded company. The CDMO projects 2022 revenues of $1 billion. What’s behind the new company?

Euroapi, a CDMO of small-molecule APIs spun off from Sanofi, has launched as a stand-alone publicly traded company. The CDMO projects 2022 revenues of $1 billion. What’s behind the new company?

New small-molecule API CDMO
Euroapi, a CDMO of small-molecule active pharmaceutical ingredients (APIs) spun off from Sanofi, has launched as a stand-alone publicly traded company. The company begins trading on the Euronext Paris stock exchange on May 6, 2022. The company’s listing on Euronext Paris followed approval earlier this week (May 3, 2022) at Sanofi’s Ordinary and Extraordinary Shareholders’ Meeting of distribution of approximately 58% of Euroapi’s shares to Sanofi shareholders with a distribution ratio of one Euroapi shares per 23 Sanofi shares.

Sanofi had announced its plan to form the stand-alone CDMO in February 2020. The new company combines Sanofi’s API commercial and development activities from six of its European production sites: Brindisi, Italy; Frankfurt, Germany; Haverhill, UK; St. Aubin les Elbeuf, France; Vertolaye, France; and Újpest, Hungary (see Figure 1). Sanofi says it expects the new manufacturing company to bring in EUR 1 billion ($1.05 billion) in sales in 2022 and that the stand-alone company will rank number one in small-molecule APIs and number two in the global API market. The new company will have a portfolio of approximately 200 APIs over the six sites (see Figure 1). In 2021, the business posted net sales of EUR 892.8 million ($941.7 million). Karl Rotthier, formerly CEO Centrient Pharmaceuticals, a Rotterdam, the Netherlands-based manufacturer of intermediates and APIs, was named as CEO of Euroapi, effective January 2021.

Sanofi is furthering its support for the CDMO by establishing a long-term customer relationship with Euroapi and has committed to holding a minority stake of approximately 30% in the CDMO for a two-year lock-up period. In addition, EPIC Bpifrance, a French public investment bank owned by the French government, has agreed to purchase 12% of EuroAPI’s shares from Sanofi and has committed to a two-year lock-up period, and L’Oréal, Sanofi’s largest shareholder, has committed to a one-year lock-up period.

Euroapi and Sanofi’s industrial footprint
When first announcing the launch of the new CDMO in 2020, Sanofi said that the new European company will help balance “the industry’s heavy reliance on API sourced from other regions” while simplifying Sanofi’s industrial footprint.

At the end of 2021, Sanofi conducted industrial production at 67 sites in 31 countries as outlined below:

  • 8 sites for its Specialty Care operations;
  • 30 sites for its General Medicines operations;
  • 6 sites for its Third-Party API operations;
  • 12 sites for its Consumer Healthcare operations; and
  • 11 sites for the industrial operations of Sanofi Pasteur in vaccines.

As of December 31, 2021, Euroapi represented approximately 1% of the total consolidated assets of Sanofi, mainly in the form of dedicated industrial facilities at the chemicals sites included in the spin-out and API inventories manufactured and commercialized by Euroapi.

Looking at Sanofi’s industrial footprint as a whole, as of December 31, 2021, Sanofi’s commitments for future capital expenditures amounted to EUR 769 million ($811 million). The principal locations involved were: for the Pharmaceuticals segment, the industrial facilities at Frankfurt (Germany); Le Trait, Maisons-Alfort, Compiègne, and Ambares (France); Cambridge (the US); Geel (Belgium); Origgio, Anagni, Brindisi, and Scoppito (Italy); and for the Vaccines segment, the facilities at Swiftwater (the US), Toronto (Canada), Marcy-l’Étoile, Neuville-sur-Saône, and Val-de-Reuil (France), and Singapore.

Sanofi’s Specialty Care industrial operations are organized around two end-to-end clusters around four dedicated biotechnology hubs: Paris/Lyon (France); Frankfurt (Germany); Geel (Belgium) and the Boston area (the US). The Bioatrium project, a joint venture between Sanofi and Lonza (Switzerland) set up in 2017 to increase bioproduction capacity, is proceeding on schedule.  The Waterford (Ireland) and Le Trait (France) sites manufacture pre-filled Dupixent (dupilumab), Sanofi’s drug for treating allergic diseases such as eczema, asthma, and nasal polyps that result in chronic sinusitis.

Sanofi’s General Medicines industrial operations are organized through end-to-end clusters, with chemistry, pharmaceutical, and injectable sites organized through a network of over 31 regional and local industrial sites in 20 countries. The manufacturing for its General Medicines business encompasses a dedicated launch sites cluster from API manufacturing to finished goods packaging (Sisteron (France), Aramon (France), Ambarès (France), and Scoppito (Italy)). The Frankfurt facility is the principal site for the manufacture of diabetes treatments.

The pharmaceutical industrial operations of its Consumer Healthcare (CHC) business are spread across a dedicated network at Sanofi’s facilities in Compiègne (France) and Cologne (Germany). The company also brought in various manufacturing operations related to its 2017 acquisition of Boehringer Ingelheim’s consumer healthcare business in-house, mainly to its sites at Compiègne (France) and Suzano (Brazil).

The industrial operations of Sanofi Pasteur, Sanofi’s vaccines business, are in a major investment phase, preparing for upcoming growth in its influenza and polio/pertussis/Hib franchises, plus the mid-term growth linked to the company’s new vaccines pipeline. Major investments were announced in 2020 and 2021 with a new Evolutive Facility in France (Neuville-Sur-Saone) and a new facility in Singapore. Other major investments are underway in France (including construction of a new influenza vaccine building at Val-de-Reuil), in Canada (a new pertussis vaccine building), and investments in the US and Mexico.

Recent Feature Articles

Manufacturing and Supply: The Impact Factors for 2023
By

By
What are key issues impacting bio/pharma manufacturing and supply in 2023? DCAT Value Chain Insights takes an inside look at what is on the industry’s radar.

Global Spending & Demand for Medicines: Up or Down?
By

By
Global demand & spending for medicines will increase to $1.9 trillion by 2027. COVID-19 vaccines will continue to be a growth driver, but what else is in play?

The Year Ahead: What’s on the Minds of CEOs?
By

By
Economic uncertainty, supply chain, talent management, and risk mitigation were key issues cited by CEOs in PwC’s Global CEO survey, released at the World Economic Forum in Davos, Switzerland. What are key takeaways from a study of 4,400 CEOs?

Big Pharma’s Growth Initiatives in 2023: Part 2
By

By
More coverage of the J.P. Morgan Annual Healthcare Conference in San Francisco earlier this month, where bio/pharma industry executives highlighted their companies’ strategies and key growth initiatives. What are more highlights?